Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. (PGNY) generates a steady flow of news as a global leader in women’s health and family building solutions listed on the Nasdaq Global Select Market. Company updates frequently focus on fertility and women’s health benefits, research on employee and member needs, and financial performance, giving investors and benefits professionals insight into how Progyny’s model is evolving.
News coverage commonly includes quarterly earnings results and financial guidance, which are also referenced in the company’s Form 8-K filings. These releases discuss revenue from fertility benefit services and pharmacy benefit services, member engagement trends, client additions, and key metrics such as assisted reproductive treatment cycles and utilization rates. Investors following PGNY news can see how changes in client count, covered lives, and engagement influence the company’s reported results and outlook.
Progyny also issues news about new programs and product expansions. For example, it has announced pregnancy, postpartum, and menopause programs for global employers that complement its existing global fertility and family building offering, along with details on features such as Global Care Advocates, knowledge centers, and country-specific navigator support. These announcements provide context on how Progyny is extending its reach across the women’s health continuum and into global markets.
Another important category of news involves research and thought leadership. Progyny has released studies on men’s fertility experiences and on gaps between employee expectations and employer offerings in women’s health benefits, conducted with Dynata. These stories highlight barriers such as stigma, cost, and benefit complexity, and they underscore the company’s focus on data-driven insights for employers.
Additional news items may cover conference participation, leadership recognition, and partnerships, such as appearances at healthcare conferences and recognition of the CEO as a Champion for Women’s Health by the World Economic Forum and the Global Alliance for Women’s Health. For anyone tracking PGNY, this news page offers a centralized view of operational, financial, and strategic developments over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Progyny, Inc. (Nasdaq: PGNY) will report its financial results for the quarter ending March 31, 2023, on May 8, 2023, after market close. The company will host a conference call at 4:45 PM ET to discuss these results. Interested participants can access the call by dialing specific numbers provided for U.S. and international participants using the passcode 265484. An audio replay will be available until May 15, 2023. Progyny specializes in fertility benefits management, offering comprehensive solutions that include education, access to specialists, and cost reduction for employers. The company has received recognition from several reputable organizations for its growth and leadership in the healthcare sector.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, is partnering with RESOLVE: The National Infertility Association to raise awareness during National Infertility Awareness Week 2023. This includes lighting the Empire State Building in orange and ringing the Nasdaq Closing Bell on April 25, 2023. The CDC reports that 1 in 5 married women in the U.S. face infertility issues, highlighting the struggles many endure to build families. Progyny’s CEO, Pete Anevski, emphasizes the company’s commitment to supporting individuals facing infertility, with successful outcomes for tens of thousands so far. The ceremony aims to amplify this message, reaching audiences beyond New York City. Celebrities like Adrienne Bailon-Houghton are also involved, advocating for increased access to family building care. This collaboration reflects a significant step in addressing infertility stigma.
Progyny, Inc. (Nasdaq: PGNY) recently appointed Dr. Janet Choi as Chief Medical Officer, leveraging over 20 years of experience in reproductive health. Formerly the Medical Director at CCRM New York, Dr. Choi will advance the company’s clinical strategy in family building benefits. Her leadership aims to enhance quality and effectiveness in care, emphasizing the importance of inclusive employer-sponsored benefits. Dr. Choi is a recognized expert, having been featured in New York Magazine’s Top Doctors and Castle Connolly’s 'Top Doctors.' This strategic addition signals Progyny's commitment to pioneering solutions in women's health and fertility benefits.
FAQ
What is the current stock price of Progyny (PGNY)?
What is the market cap of Progyny (PGNY)?
